Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04670302
Other study ID # 1208/KEPK/V/2019
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 17, 2019
Est. completion date December 31, 2022

Study information

Verified date December 2020
Source Dr. Soetomo General Hospital
Contact Heri Suroto, MD, PhD
Phone 62 31 5038335
Email hsuroto2000@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized clinical trial conducted in a single tertiary hospital which investigates the efficacy of allogeneic adipose-derived mesenchymal stem cells and human amniotic membrane (AAdMSC-HAM) composite for supraspinatus tendon repair augmentation


Description:

Supraspinatus tendon tear is the most common factor causing shoulder pain, mainly resulting in discomfort and functional deficit in individuals over the age of 35. Supraspinatus tendon repair surgery represents one of the most widely performed types of orthopedic operation. Nevertheless, concerns persist regarding tendon-to-bone healing during the postoperative period. Despite advancements in surgical technique, re-tear of a previously repaired supraspinatus tendon is a fairly common complication, especially in a larger size tear. Such repair technique employing suture anchor devices alone has not yet produced functional results demonstrating both anatomical and biomechanical properties. Therefore, tendon tissue engineering using a combination of scaffolds, cells, and growth factors stimulation offers a potential solution as a biological augmentation in tendon repair. Human amniotic membrane (HAM) has been widely used as a natural scaffold in tissue engineering due to many of its unique properties such as providing growth factors, cytokines and tissue inhibitors of metalloproteinases, adequate mechanical strength, and biocompatibility. Whereas, mesenchymal stem cells (MSCs) constitute one of the adult stem cells that promote replacement and repair of damaged tissue along with normal tissue turnover. These MSCs are seeded to the HAM scaffolds to biologically augment tendon repair, with MSCs acting as cytokines/growth factors to stimulate tissue repair. This approach serves as the foundation to conduct the present study. The investigators aim to investigate the efficacy of using allogeneic adipose-derived MSCs and human amniotic membrane (AAdMSC-HAM) composite for supraspinatus tendon repair augmentation.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 75 Years
Eligibility Inclusion Criteria: - Suffering from complete/total tear of supraspinatus tendon for a duration of fewer than 12 months - Diagnosis is established based on clinical condition and ultrasonography or MRI examination Exclusion Criteria: - Patients with comorbid diseases: Diabetes Mellitus, Rheumatoid Arthritis, and other inflammatory diseases. - Patients presenting with other related injuries, such as fractures or dislocation around the shoulder joint.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Tendon repair procedure
Tendon repair procedure: Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon. Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity. Then, double suturing of the supraspinatus tendon is performed.
Tendon repair augmented with AAdMSC-HAM composite
After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.

Locations

Country Name City State
Indonesia Dr. Soetomo General Academic Hospital/ Department Orthopaedic & Traumatology Faculty of Medicine Universitas Airlangga Surabaya East Java

Sponsors (1)

Lead Sponsor Collaborator
Dr. Soetomo General Hospital

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Active range of motion (AROM) pre-surgery Shoulder: flexion, extension, abduction, adduction, external rotation, internal rotation.
The tests are performed by two blinded assessor, and expressed in degrees.
Pre-surgery
Primary Active range of motion (AROM) at 12 months follow-up Shoulder: flexion, extension, abduction, adduction, external rotation, internal rotation.
The tests are performed by two blinded assessor, and expressed in degrees.
12 months
Secondary Pain pre-surgery Measured by visual analogue scales (VAS). Patients are asked to described their level of pain from the scale 0 to 10 (0 indicating no pain, 1-3 indicating mild pain, 4-6 indicating moderate pain, 7-9 indicating severe pain, and 10 indicating the worst, unbearable pain). The lower scores mean a better pain outcome Pre-surgery Outcome
Secondary Pain at follow-up 12 months Measured by visual analogue scales (VAS). Patients are asked to described their level of pain from the scale 0 to 10 (0 indicating no pain, 1-3 indicating mild pain, 4-6 indicating moderate pain, 7-9 indicating severe pain, and 10 indicating the worst, unbearable pain). The lower scores mean a better pain outcome 12 months
Secondary Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery DASH score is a self-assessment of symptoms and function of the entire upper extremity comprising 30 items. Each item consists of five levels of answers (1=no difficulty/symptoms, 2=mild difficulty/symptoms, 3=moderate difficulty/symptoms, 4=severe difficulty/symptoms, and 5=extreme difficulty (unable to do)/symptoms). The scores are then used to calculate a scale score ranging from 0 (no disability) to 100 (most severe disability). Greater DASH scores reflect greater disability (worse outcome). Pre-surgery
Secondary Disabilities of the Arm, Shoulder, and Hand (DASH) score at follow-up 12 months DASH score is a self-assessment of symptoms and function of the entire upper extremity comprising 30 items. Each item consists of five levels of answers (1=no difficulty/symptoms, 2=mild difficulty/symptoms, 3=moderate difficulty/symptoms, 4=severe difficulty/symptoms, and 5=extreme difficulty (unable to do)/symptoms). The scores are then used to calculate a scale score ranging from 0 (no disability) to 100 (most severe disability). Greater DASH scores reflect greater disability (worse outcome). 12 months
Secondary Constant-Murley Score (CS) pre-surgery The scoring system records individual parameters and provides an overall clinical functional assessment. It consists of 4 domains: pain, activities of daily living (ADL), mobility, and power/strength. Pain and ADL are self-assessed, while all other items are assessed by the blinded examiner. A higher score shows a better function (100 as the best), while a lower score shows a worse function (0 as the worst). Pre-surgery
Secondary Constant-Murley Score (CS) at follow-up 12 months The scoring system records individual parameters and provides an overall clinical functional assessment. It consists of 4 domains: pain, activities of daily living (ADL), mobility, and power/strength. Pain and ADL are self-assessed, while all other items are assessed by the blinded examiner. A higher score shows a better function (100 as the best), while a lower score shows a worse function (0 as the worst). 12 months
Secondary Tear recurrence (re-tear) A systematic review (D'Ambrosi et al., 2019) showed that re-tear rates after rotator cuff repair with scaffolds were 17.97%. We hypothesize that the augmentation using HAM (as scaffold) seeded with AAdMSC would further lower the re-tear rates. We plan to record the recurrence of supraspinatus tendon tear (if any) based on radiographic evaluation with ultrasonography, which will then be confirmed with MRI. Ultrasonography provides an excellent anatomical evaluation of soft tissue which is able to assess any alterations during active locomotion. However, due to its user-dependent nature, we will also confirm the findings with MRI examination. Any grade of re-tear (grade I-III as evaluated by ultrasonography and confirmed with MRI) will be counted in and classified as "re-tear". When the patients do not complain about any symptoms of re-tear, we will record them as "no re-tear". Throughout the study duration (12 months), recorded as the first time complained by the patients (i.e. after "n" months).
See also
  Status Clinical Trial Phase
Recruiting NCT05590494 - Novel Treatment for Rotator Cuff Tears N/A
Enrolling by invitation NCT01414764 - Does Autologous Conditioned Plasma Enhance Rotator Cuff Tendon Healing After Surgery? Phase 3
Active, not recruiting NCT04444076 - Clinical Trial on the Effect of REGENETEN Bioinductive Implant in the Supraspinatus Tendon Repair. N/A
Recruiting NCT05660031 - Treatment of the Biceps With Concomitant Supraspinatus Tears N/A
Completed NCT03942679 - Platelet Rich Plasma and Supraspinatus Tear N/A
Completed NCT03084068 - Use of Human Dehydrated Umbilical Cord Allograft in Supraspinatus Tendon Repair N/A
Enrolling by invitation NCT05335785 - Efficacy of High Intensity Lazer Therapy in Partial Supraspinatus Tear N/A